Novavax receives global approvals for updated Nuvaxovid COVID-19 vaccine
Novavax has received regulatory approvals in the U.S., European Union, and Japan for its updated version of the protein-based Nuvaxovid vaccine. The approval was granted after adjustments to address current strains of the virus. This development marks a significant milestone as it expands access to an improved formulation that could be more effective against evolving variants. The collaboration with Sanofi and Takeda played a key role in bringing this updated version to market, highlighting continued international efforts to adapt vaccine strategies amid ongoing public health needs. The approvals are expected to support broader distribution of the vaccine globally, potentially increasing demand for Novavax's product.
Topics: covid-19 pharmaceuticals vaccine